Companies in #Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
Found 1 company operating in this sector.
Omeros Corporation is a Seattle-based biopharmaceutical company developing small-molecule and biologic therapies for complement-mediated diseases, immune-related disorders, and central nervous system conditions. Its first commercial product, Yartemlea (narsoplimab), is the first FDA-approved treatment for transplant-associated thrombotic microangiopathy (TA-TMA) in hematopoietic stem cell transplantation.